MBS Digest curates recent research, policy, access, and market signals for bariatric surgeons and obesity medicine specialists. This issue keeps the focus on practical program decisions: how to govern patient-facing AI, how to reduce supplement nonadherence, how to frame concurrent hernia repair and reoperative surgery, and how to interpret a fast-moving incretin pipeline without losing the role of durable surgical care.

This tracker follows a bariatric-adjacent cohort across robotics, medtech, orthopedics, cardiometabolic pharma, specialty pharma, managed care, and hospital operations. Prices were pulled from Yahoo Finance chart data at assembly on June 10, 2026. The 90-day performance window begins with the first available trading close on or after the 90-day lookback date.

The strongest 90-day performer in this cohort was UNH at +46.7%, while HCA lagged at -30.1%. The split is useful for MBS readers because it separates procedure-volume exposed medtech and hospitals from broader pharmaceutical and payer names. It also shows that obesity-care economics are not captured by GLP-1 manufacturers alone.

Medtech names in this set remain tied to procedure recovery, capital purchasing, implant volumes, and hospital margin discipline. Pharma and royalty names trade more on pipeline, exclusivity, and chronic-disease exposure. Managed care and hospitals add a payer-provider readout: if coverage expands for obesity medication while surgical volumes remain durable, both sides of the care pathway will feel the effect through utilization management, referral patterns, and site-of-care economics.